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Background
Maraviroc is a CCR5 antagonist with clearly demon-
strated virological efficacy in patients refractory to prior
treatment and infected with an R5-tropic virus.
This antiretroviral drug would appear to have a special
immunomodulatory property, given the significantly
higher increase in CD4 count in patients treated with
maraviroc in clinical trials.
We report the case of a severely immunocompromised
patient in which the introduction of maraviroc reduced
viral load to below the threshold of 40 copies/ml, with an
increase in CD4 of over 100 in the space of 17 months.
Methods
The patient was a 53 year old man diagnosed with HIV
in 1987, and classed stage C according to CDC classifi-
cation for cerebral toxoplasmosis in June 1995. His his-
tory includes cerebral histoplasmosis in April 1997
(relapse in April 2006) and stage IV Hodgkin’sl y m -
phoma with visceral involvement in October 2006 (CD4
=1 / m m
3). The first antiretroviral treatment was given
in October 1995 (CD4 <50/mm
3), and the first mara-
viroc-based combination therapy was his 28
th line treat-
ment (16 stoppages for treatment failure). In January
2008, the tropism test (trofile test) gave an R5 profile
and the genotypic resistance test (ANRS algorithm July
2009) showed, for the RT gene, resistance to AZT, 3TC,
D4T, ddI, ABC, EFV, NVR and possibly to TDF and
ETV; for the protease gene, resistance to IDVr, SQVr,
NFV, FPVr, ATV, DRVr, LPVr and possibly to TPVr.
Results
Table 1 shows viro-immunological changes with treatment:
Discussion
This case report shows the possibility of being con-
fronted with an R5-tropic virus after 21 years’ progres-
sion, and 15 years of antiretroviral treatment, with
severe immunosuppression. The three successive mara-
viroc-based combination therapies lead to an increase in
CD4 count independent of the virological response, with
a delta of +120 CD4 after 17 months. A parallel increase
in the CD8 count was also observed, as has been
reported in clinical trials.
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Table 1
D0 M3 M6 M12 M15 M17
VLlog/ml 3.83 2.63 5.68 1.6 1.6 1.6
CD4/mm
3 82 138 132 147 207 200
CD4% 11.4 13.5 13.1 12.2 15.1 15.1
CD8/mm
3 346 445 524 596 661 575
CD8% 48.3 43.7 51.7 49.5 48.3 43.5
MVC add
to
FTC/RAL/ETV
1 month
TPVr/ETV
5 months
TVD/DRVr/ETV
12 months
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